Malik P - Search Results

1

Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies.

Malik P, Edginton A. Malik P, et al. Expert Opin Drug Metab Toxicol. 2018 Jun;14(6):585-599. doi: 10.1080/17425255.2018.1482278. Epub 2018 Jun 4. Expert Opin Drug Metab Toxicol. 2018. PMID: 29806953 Review.

2

Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.

Malik PRV, Hamadeh A, Phipps C, Edginton AN. Malik PRV, et al. J Pharmacokinet Pharmacodyn. 2017 Jun;44(3):277-290. doi: 10.1007/s10928-017-9515-3. Epub 2017 Mar 4. J Pharmacokinet Pharmacodyn. 2017. PMID: 28260166

3

Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients.

Malik PRV, Edginton AN. Malik PRV, et al. CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):835-844. doi: 10.1002/psp4.12456. Epub 2019 Oct 19. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31343836 Free PMC article.

4

Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants.

Malik PRV, Edginton AN. Malik PRV, et al. J Clin Pharmacol. 2020 Apr;60(4):466-476. doi: 10.1002/jcph.1540. Epub 2019 Nov 14. J Clin Pharmacol. 2020. PMID: 31729044

5

A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease.

Malik PRV, Yeung CHT, Ismaeil S, Advani U, Djie S, Edginton AN. Malik PRV, et al. J Clin Pharmacol. 2020 Oct;60 Suppl 1:S52-S62. doi: 10.1002/jcph.1713. J Clin Pharmacol. 2020. PMID: 33205424

6

Pediatric Dose Selection for Therapeutic Proteins.

Malik PRV, Temrikar ZH, Chelle P, Edginton AN, Meibohm B. Malik PRV, et al. J Clin Pharmacol. 2021 Jun;61 Suppl 1:S193-S206. doi: 10.1002/jcph.1829. J Clin Pharmacol. 2021. PMID: 34185910 Review.

7

Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.

Malik PRV, Hamadeh A, Edginton AN. Malik PRV, et al. Pharm Res. 2022 Feb;39(2):239-250. doi: 10.1007/s11095-022-03177-2. Epub 2022 Feb 3. Pharm Res. 2022. PMID: 35118567

8

Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Malik P, Phipps C, Edginton A, Blay J. Malik P, et al. Pharm Res. 2017 Dec;34(12):2579-2595. doi: 10.1007/s11095-017-2259-3. Epub 2017 Sep 18. Pharm Res. 2017. PMID: 28924691 Review.

9

Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling.

Dubinsky S, Malik P, Hajducek DM, Edginton A. Dubinsky S, et al. Among authors: malik p. Clin Pharmacokinet. 2022 Jul;61(7):997-1012. doi: 10.1007/s40262-022-01121-6. Epub 2022 May 5. Clin Pharmacokinet. 2022. PMID: 35508593

10

Predicting Escitalopram Exposure to Breastfeeding Infants: Integrating Analytical and In Silico Techniques.

Delaney SR, Malik PRV, Stefan C, Edginton AN, Colantonio DA, Ito S. Delaney SR, et al. Clin Pharmacokinet. 2018 Dec;57(12):1603-1611. doi: 10.1007/s40262-018-0657-2. Clin Pharmacokinet. 2018. PMID: 29651785

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

804 results

Search Page

Filters